NASDAQ:PLSE
Pulse Biosciences, Inc.
Pulse Biosciences, Inc.'s revenue was $350,000 in fiscal 2025. Free cash flow was −$54.4M, −15553.4% of revenue.Summary generated from Pulse Biosciences, Inc.'s SEC filings. Latest annual report filed Feb 19, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$350,000
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross margin−54.0%
Operating margin−21982.6%
Net margin−20794.6%
ROICn/a
Return on equity−74.4%
Debt / equityn/a
Free cash flow−$54.4M
FCF margin−15553.4%
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 | 1 | 0 | 0 | 0 |
| Operating income | −63 | −58 | −44 | −56 | −77 |
| Net income | −64 | −59 | −42 | −54 | −73 |
| Free cash flow | −55 | −47 | −33 | −36 | −54 |
Recent filings
- 8-KOther events
Oct 7, 2026 - 8-KEntry into a material agreement
Sep 15, 2026 - 8-KOther events
Sep 15, 2026 - 4Insider transaction report
Sep 2, 2026 - 4Insider transaction report
Aug 28, 2026 - 8-KEntry into a material agreement
Aug 6, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026